CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1

What is the purpose of this trial?

The study is a 2-arm, multicenter, 1:1 randomized, placebo controlled clinical trial.

All subjects will receive close monitoring for development of AGT or T1DM. Subjects will receive Abatacept or placebo and close monitoring for development of AGT or T1DM. To assess the safety, efficacy, and mode of action of Abatacept to prevent AGT and T1DM.

The primary objective is to determine whether intervention with Abatacept will prevent or delay the development of AGT in at-risk autoantibody positive non-diabetic relatives of patients with T1DM.

Secondary outcomes include: the effect of Abatacept on the incidence of T1DM analyses of C-peptide and other measures from the OGTT safety and tolerability and mechanistic outcomes.


Participation Guidelines

Ages: 6 - 45 years

Gender: Both


National Institute of Diabetes and Digestive & Kidney Diseases

Start Date: 05/07/2013

End Date: 03/01/2017

Last Updated: 02/22/2018

Study HIC#: 1211011152

Get Involved

For more information about this study, contact:
Laurie Feldman
+1 203-737-2760
laurie.feldman@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Kevan Herold

Principal Investigator

Sub-Investigators